1. Taiwan Stocks

  2. •

    Commercial services

  3. •

    Miscellaneous commercial services
Bio Preventive Medicine Corp.

Bio Preventive Medicine Corp.

TTPEX:6810
20.50
TWD
-0.15
(-0.73%)
1.14BMarket Cap
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
0.03
0.06
0.04
0.35
0.05
- -
Basic EPS, GAAP
-0.2
-0.25
-1.99
-1.98
-2.03
-2.16
-2.47
-2.02
- -
Free Cash Flow per Basic Share
-0.19
-0.16
-1.43
-1.41
-5.93
-1.94
-1.9
-1.95
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
4.74
5.39
5.93
4.05
3.89
3.67
8.23
6.21
5.25
Tangible Book Value per Share
3.97
4.7
5.31
3.51
3.44
3.3
8
6.03
5.09
Basic Weighted Avg Shares
279
292
33
34
35
34
36
49
49
Sales/Revenue/Turnover
- -
- -
- -
1
2
1
12
3
- -
Operating Margin (%)
- -
- -
- -
-7,698.05
-3,252.69
-6,006.95
-697.44
-3,832.05
- -
Depreciation Expense
12
20
21
21
16
8
8
7
- -
Net Income, GAAP
-57
-73
-65
-67
-71
-73
-88
-100
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
-7,709.52
-3,258.61
-6,066.64
-712.04
-3,800.8
- -
Working Capital
89
113
146
95
76
75
345
245
198
LT Debt
- -
11
5
- -
113
106
102
96
94
Total Equity
161
183
202
138
141
140
407
307
260
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-42.19
-33.66
-39.58
-50.95
-52.26
-32.01
-27.96
- -

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
5
5
5
LT Borrowings
99
96
94
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
49
49
49
Market Capitalization
1,483
1,157
1,140

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
314
267
215
Cash, Cash Equivalents & STI
300
251
199
Accounts Receivable, Net
- -
- -
1
Inventories
1
1
1
Total Current Liabilities
16
22
17
Payables & Accruals
- -
- -
- -
ST Debt
5
5
5
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
27.24%
-24.53%
Free Cash Flow
- -
62.57%
43.04%
Net Income, GAAP
- -
9.21%
14.03%
Sales/Revenue/Turnover
- -
- -
-78.64%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
12
2025
- -
- -
3
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-2.47
2025
- -
- -
-2.02
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Tzu Ling Tseng
Full Time Employees
30
Sector
Commercial services
Industry
Miscellaneous commercial services
Address
No.18, Taiyuan Street Zhubei Taiwan 302
IPO Date
Aug 30, 2021
Website
bpmbiotech.com
Similar Companies
PayPal Holdings, Inc. (NASDAQ:PYPL)
Shopify Inc. (NASDAQ:SHOP)
Greenland Mines Ltd (NASDAQ:GRML)
Block, Inc. (NYSE:XYZ)
Netcapital Inc. (NASDAQ:NCPL)
Shopify, Inc. Class A (TSX:SHOP)
Business
Bio Preventive Medicine Corp (6810.TWO) develops and commercializes molecular diagnostic products and testing services for early detection and prevention of chronic diseases and cancers. The company offers in vitro diagnostic reagents and non-invasive urine tests, including the patented DNlite series such as DNlite-IVD103 and DNlite-DN_Score for monitoring diabetic kidney disease progression and diabetic nephropathy; solutions for chronic kidney disease, diabetes complications and other chronic conditions; biomarker-based diagnostics for oncology applications. Founded in 2014 as an Industrial Technology Research Institute spin-off and headquartered at 6F-1, No. 18 Taiyuan Street, Zhubei City, Hsinchu County, Taiwan, Bio Preventive Medicine operates in North America, Europe, Asia and South America markets, targeting healthcare providers, pharmaceutical partners and patients with unmet needs in precision medicine. The company maintains its focus on high-value translational research without major recent acquisitions, partnerships, funding rounds or product launches reported in the last two years.